• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ICON plc

    10/25/24 9:08:10 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email
    S-8 1 forms-8.htm S-8 Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ICON PUBLIC LIMITED COMPANY
    (Exact name of registrant as specified in its charter)
        
    Ireland
    98-1067160
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)
    South County Business Park
    Leopardstown
    Dublin 18, Ireland
    (Address of Principal Executive Offices)
    (Zip Code)
    ICON plc 2013 Employees Restricted Share Unit Plan
    (as amended and restated effective as of November 6, 2024)
    (Full title of the plan)
    Cahill Gordon & Reindel LLP
    32 Old Slip
    New York, New York  10005
    Attention:  Helene R. Banks, Esq.
    (Name and address of agent for service)
    (212) 701-3000
    (Telephone number, including area code, of agent for service)
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☒
    Accelerated filer ☐
    Non-accelerated filer ☐ (Do not check if a smaller reporting company)
    Smaller reporting company ☐




    EXPLANATORY NOTE
    This Registration Statement is solely for the registration of an additional 2,500,000 Ordinary Shares of ICON plc for issuance under the ICON plc 2013 Employees Restricted Share Unit Plan (as amended and restated effective as of November 6, 2024) (the “RSU Plan”). Pursuant to General Instruction E to Form S-8, the contents of the following earlier registration statements relating to the RSU Plan are incorporated herein by reference to the extent not supplemented, amended or superseded by the information set forth in this Registration Statement on Form S-8: Registration Statement No. 333-190068 and Registration Statement No. 333-204153.
    Part I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    Item 1.    Plan Information.*
    Item 2.    Registrant Information and Employee Plan Annual Information.*
    *    Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement (this “Registration Statement”) in accordance with Rule 428 under the Securities Act of 1933, as amended, and the Note to Part I of Form S-8.
    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3.    Incorporation of Documents by Reference.
    The following documents have been filed with the Securities and Exchange Commission (the “Commission”) by ICON plc (“ICON” or the “Registrant”) and are hereby incorporated by reference into this Registration Statement:
    •ICON’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the Commission on February 23, 2024; and
    •The description of ICON’s ordinary shares, par value 6 euro cents each (the “Ordinary Shares”) incorporated by reference to ICON’s Registration Statement on Form F-3 (File No. 333-133371) filed with the Commission on April 19, 2006, as amended on May 5, 2006.
    In addition, all documents subsequently filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents.
    Item 4.    Description of Securities.
    Not applicable.
    Item 5.    Interests of Named Experts and Counsel.
    Not applicable.
    2



    Item 6.    Indemnification of Directors and Officers.
    Article 141 of ICON’s articles of association provide that, subject to the provisions of, and so far as may be permitted by the Irish Companies Act, 2014, as amended (the “Irish Companies Act”) every director, managing director, secretary or other officer of ICON shall be entitled to be indemnified by ICON against all costs, charges, losses, expenses, and liabilities incurred by him or her in the execution and discharge of his or her duties or in relation thereto including any liability incurred by him or her in defending any proceedings, civil or criminal, which relate to anything done or omitted or alleged to have been done or omitted by him or her as an officer or employee of ICON and in which judgment is given in his or her favor (or the proceedings are otherwise disposed of without any finding or admission of any material breach of duty on his or her part) or in which he or she is acquitted or in connection with any proceedings or any application under the Act or under any statute for relief from liability in respect of any such act or omission in which relief is granted to him or her by the Court.
    To the extent permitted by law, ICON’s directors may arrange insurance cover at the cost of ICON in respect of any liability, loss or expenditure incurred by any director or officer in relation to anything done or alleged to have been done or omitted to be done by him or her as director or officer.
    Item 7.    Exemption from Registration Claimed.
    Not applicable.
    Item 8.    Exhibits.
    The following is a complete list of exhibits filed or incorporated by reference as a part of this Registration Statement:
    Exhibit No .Description
    4.1
    ICON plc 2013 Employees Restricted Share Unit Plan, amended and restated effective as of November 6, 2024.
    5.1
    Opinion of A&L Goodbody Solicitors with respect to the legality of the Ordinary Shares being registered hereby.
    23.1
    Consent of KPMG.
    23.2
    Consent of A&L Goodbody (included in Exhibit 5.1)
    24.1
    Power of Attorney (included on the signature page hereof)
    107
    Filing Fee Table

    Item 9.    Undertakings.
    A.    The undersigned Registrant hereby undertakes:
    (1)     To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
        (i)     To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;
    3



        (ii)     To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;
        (iii)     To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;
    provided, however, that:
    paragraphs (A)(1)(i) and (A)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in this Registration Statement.
    (2)     That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)     To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (4)     The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (5)     Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
    4



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland on October 25, 2024.
    ICON PLC
    By:/s/ Brendan Brennan
    Name:Brendan Brennan
    Title:Chief Financial Officer




    POWER OF ATTORNEY
    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Stephen Cutler and Diarmaid Cunningham, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign the Registration Statement on Form S-8 under the Securities Act of 1933, as amended, to sign any and all pre- or post-effective amendments to the Registration Statement on Form S-8, and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated.
    SignatureTitleDate
    /s/ Stephen Cutler Chief Executive Officer and Director
    October 25, 2024
    Stephen Cutler
    /s/ Ciaran Murray Chairman and Director
    October 25, 2024
    Ciaran Murray 
    /s/ Brendan Brennan
    Chief Financial Officer and Principal Accounting Officer
    October 25, 2024
    Brendan Brennan 
    /s/ John Climax
    Director
    October 25, 2024
    John Climax 
    /s/ Rónán Murphy
    Director
    October 25, 2024
    Rónán Murphy
    /s/ Eugene McCague
    Director
    October 25, 2024
    Eugene McCague
    /s/ Julie O’Neill
    Director
    October 25, 2024
    Julie O’Neill
    /s/ Linda Grais
    Director
    October 25, 2024
    Linda Grais
    /s/ Anne Whitaker
    Director
    October 25, 2024
    Anne Whitaker



    AUTHORIZED REPRESENTATIVE
    Puglisi & Associates
    /s/ Donald J. Puglisi__________________
    Authorized Representative in the United States
    October 25, 2024
    Donald J. Puglisi
    Managing Director, Puglisi & Associates

    Get the next $ICLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    1/8/2026$222.00Buy → Hold
    Truist
    12/15/2025$195.00Buy → Neutral
    BofA Securities
    11/13/2025$175.00Market Perform
    BMO Capital Markets
    9/9/2025$175.00Buy → Hold
    Jefferies
    9/3/2025$236.00Neutral → Buy
    Rothschild & Co Redburn
    8/21/2025$200.00Buy → Neutral
    Citigroup
    7/24/2025$224.00Neutral → Outperform
    Robert W. Baird
    4/29/2025$150.00Overweight → Neutral
    Analyst
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ICON plc downgraded by Truist with a new price target

    Truist downgraded ICON plc from Buy to Hold and set a new price target of $222.00

    1/8/26 8:39:35 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc downgraded by BofA Securities with a new price target

    BofA Securities downgraded ICON plc from Buy to Neutral and set a new price target of $195.00

    12/15/25 9:55:49 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BMO Capital Markets initiated coverage on ICON plc with a new price target

    BMO Capital Markets initiated coverage of ICON plc with a rating of Market Perform and set a new price target of $175.00

    11/13/25 9:13:59 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership

    ICON plc (NASDAQ:ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois. The new institute strengthens Accellacare's ability to support oncology clinical trials and broaden access to innovative cancer treatments for patients. The Brian Moran Cancer Institute includes: ‒ 14 medical oncologists ‒ Three radiation oncologists ‒ Nine fellowship-trained surgical specialists in urologic oncology, breast surgery, colorectal surgery, endocrine surgery, and general surgical oncology This development builds on Accellacare's existing oncology exp

    1/27/26 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. I

    12/9/25 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, a

    12/2/25 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    SEC Filings

    View All

    SEC Form 6-K filed by ICON plc

    6-K - ICON PLC (0001060955) (Filer)

    1/7/26 4:15:46 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by ICON plc

    SCHEDULE 13G - ICON PLC (0001060955) (Subject)

    11/14/25 12:59:35 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by ICON plc

    SCHEDULE 13G - ICON PLC (0001060955) (Subject)

    11/12/25 9:33:32 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    View All

    ICON Announces CEO Transition

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the

    9/4/25 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Announces Results of Annual General Meeting

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

    7/23/25 4:20:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Anne Whitaker Appointed as Non-Executive Director

    MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

    4/3/25 6:13:56 PM ET
    $ICLR
    $TLX
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICLR
    Financials

    Live finance-specific insights

    View All

    ICON Reports Third Quarter 2025 Results

    Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing an increase of 0.7% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1.4% on quarter two 2025; a net book to bill in the quarter of 1.02. Net debt was $2.9 bil

    10/22/25 4:25:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc Schedules Third Quarter 2025 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation. From molecule

    9/24/25 9:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Reports Second Quarter 2025 Results

    Highlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02. Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025. Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share. Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025. Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share. Net de

    7/23/25 4:15:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICON plc

    SC 13G/A - ICON PLC (0001060955) (Subject)

    11/12/24 11:54:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    2/9/24 11:49:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    1/30/24 12:11:57 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care